Achondroplasia had no approved treatment addressing its cause, leaving limb-lengthening surgery as the main intervention. Voxzogo (vosoritide) targeted the signaling defect directly.
By binding NPR-B, this C-type natriuretic peptide analog counteracts the overactive FGFR3 signaling that suppresses chondrocyte proliferation in the growth plates. The daily subcutaneous injection improves linear growth in children with achondroplasia who have open epiphyses.
Voxzogo’s label was expanded to younger children after initial approval, considerably broadening its treatment window. It holds orphan designation and faces no approved competitor to date, making it the incumbent that weekly and oral FGFR3-pathway candidates in development must displace.
